Methimazole vs Carbimazole: Preferred Agent and Dosing

Methimazole is the preferred antithyroid drug for treating newly diagnosed overt hyperthyroidism in non-pregnant adults, with an initial dose of 10-30 mg once daily.

Drug Selection: Methimazole Over Carbimazole

Methimazole is the drug of choice because carbimazole is rapidly converted to methimazole after absorption, making them essentially equivalent agents 1, 2, 3. The conversion ratio is approximately 0.6-1.0 (meaning 10 mg carbimazole converts to roughly 6-10 mg methimazole) 3.

Switching between these two drugs provides no benefit for managing side effects, as they share the same active metabolite and adverse effect profile 1.
In regions where both are available, methimazole is preferred due to lower cost, wider availability, and the ability to dose more precisely 2.
Cross-reactivity occurs between carbimazole and methimazole for all adverse effects, including agranulocytosis and hepatotoxicity 1.

Initial Dosing Strategy

Standard Starting Dose

For a 36-year-old woman with newly diagnosed overt hyperthyroidism, initiate methimazole 10-30 mg once daily 2, 3.

Dose selection within this range depends on disease severity:
- Mild-to-moderate hyperthyroidism (T4 <260 nmol/L): Start with 15-20 mg daily 4.
- Severe hyperthyroidism (T4 >260 nmol/L): Start with 30 mg daily 4.
Single daily dosing is as effective as divided doses because methimazole has a longer intrathyroidal half-life (>24 hours) than plasma half-life 5, 4.
Single daily dosing improves adherence and is the preferred regimen 5.

Carbimazole Equivalent Dosing (If Methimazole Unavailable)

If only carbimazole is available, the equivalent starting dose is 15-45 mg once daily (using the 0.6-1.0 conversion factor) 3.

For mild-to-moderate disease: 20 mg carbimazole daily 4.
For severe disease: 40 mg carbimazole daily 4.

Monitoring and Dose Adjustment

Check thyroid function (free T4, free T3, TSH) at 4 weeks to assess response 4.
Lower doses (15-20 mg methimazole or 20 mg carbimazole) reduce the risk of iatrogenic hypothyroidism compared to higher starting doses, particularly in patients with baseline T4 <260 nmol/L 4.
Euthyroidism is typically achieved within 3-6 weeks regardless of whether 20 mg or 40 mg carbimazole is used 5, 4.

Critical Safety Considerations

Agranulocytosis Risk

Agranulocytosis occurs in approximately 3 per 10,000 patients, typically within the first 3 months of therapy 1.
Instruct the patient to immediately seek medical attention if fever, sore throat, or malaise develops 1.
Obtain a complete blood count if these symptoms occur and discontinue the drug immediately 1.

Hepatotoxicity

Both methimazole and carbimazole can cause severe, potentially fatal hepatotoxicity (cholestatic or hepatocellular pattern) 1.
Advise the patient to report abdominal pain, nausea, or jaundice immediately 1.
Propylthiouracil carries higher hepatotoxicity risk than methimazole, particularly in children and adolescents 1.

Dose-Dependent Adverse Effects

Hypothyroidism is the most common dose-dependent side effect—monitor thyroid function regularly 1.
Neutropenia may be mild and dose-dependent, distinct from severe allergic agranulocytosis 1.

Other Adverse Effects

Pruritus and rash occur commonly—switching between methimazole and propylthiouracil may help, but cross-reactivity is possible 1.
Arthralgias develop in 1-5% of patients and may herald more serious immunologic complications (e.g., ANCA-positive vasculitis with long-term propylthiouracil use)—discontinue the drug if arthralgias occur 1.

Special Populations (Not Applicable Here, But Important Context)

Pregnancy

Propylthiouracil is preferred in the first trimester due to methimazole's association with aplasia cutis congenita and choanal/esophageal atresia 6, 1, 2.
Methimazole is preferred in the second and third trimesters due to propylthiouracil's hepatotoxicity risk 6.
This patient is non-pregnant, so methimazole is appropriate 6.

Breastfeeding

Both methimazole and propylthiouracil are safe during breastfeeding 6, 2.

Common Pitfalls to Avoid

Do not switch from carbimazole to methimazole (or vice versa) to manage side effects—they are metabolically equivalent and share adverse effect profiles 1.
Do not use divided daily dosing—single daily dosing is equally effective and improves adherence 5, 4.
Do not start with excessively high doses (>30 mg methimazole or >40 mg carbimazole)—this increases the risk of iatrogenic hypothyroidism without improving time to euthyroidism 4.
Do not delay monitoring—check thyroid function at 4 weeks to guide dose titration 4.

Summary Algorithm

Start methimazole 15-20 mg once daily for mild-to-moderate hyperthyroidism (or 30 mg for severe disease) 2, 4.
Educate the patient about agranulocytosis (fever, sore throat) and hepatotoxicity (abdominal pain, jaundice) warning signs 1.
Recheck thyroid function at 4 weeks and adjust dose accordingly 4.
Continue treatment for 12-18 months before considering discontinuation (standard duration for Graves' disease) 2.

In a 36‑year‑old non‑pregnant woman with newly diagnosed overt hyperthyroidism, which antithyroid thioamide—methimazole or carbimazole—is preferred and what is the appropriate initial daily dose?

Help us tailor your experience